toxylact: a06ad12 lactitol
The first professional lActological database in the word
Lactitol (ATC A06AD12) is an orally administered osmotic laxative, used mainly for chronic constipation, with minimal systemic absorption and a favourable safety profile that makes it generally compatible with breastfeeding, although direct data in lactating women are limited and recommendations remain cautious.medpedia.framar+4
Pharmacological class and mechanism
Lactitol is a sugar alcohol (disaccharide alcohol) produced by catalytic hydrogenation of lactose and classified within osmotically acting laxatives (ATC A06AD12). It is structurally related to sorbitol and behaves pharmacologically as a poorly absorbed carbohydrate in the gut lumen.sciencedirect+4
After oral administration, lactitol reaches the colon largely unmetabolised, where it exerts an osmotic effect, increasing intraluminal fluid, softening stools and promoting colonic peristalsis and stool propulsion.drugs+4
Colonic bacteria ferment lactitol to short‑chain fatty acids, leading to a reduction in luminal pH and favourable modulation of the intestinal microbiota, which supports a prebiotic effect at low doses without major intolerance symptoms.pubmed.ncbi.nlm.nih+3
Therapeutic indications and dosing
Lactitol is indicated for the treatment of chronic idiopathic constipation in adults, as reflected in its ATC classification and regulatory approvals.drugbank+4
In some regions it is also used orally for the prevention and treatment of hepatic encephalopathy, aiming to reduce ammonia absorption through laxative and microbiota‑modulating effects.drugs.ncats+2
Standard adult dosing for chronic idiopathic constipation is around 20 g once daily with food, with possible adjustment down to 10 g once daily in case of persistent loose stools; Bulgarian practice information also cites 10 g once daily as a typical regimen.farmacotherapeutischkompas+4
Paediatric doses, where authorised, are generally weight‑based (for example approximately 0.25 g/kg/day, or 10–15 ml syrup daily depending on age), and require individual titration under medical supervision.mims+1
Pharmacokinetics and systemic exposure
Following oral administration, lactitol is minimally absorbed from the gastrointestinal tract, and the majority of the dose remains within the lumen to exert local osmotic and prebiotic effects.accessdata.fda+2
Clinical pharmacology data indicate that after a single 21 g oral dose, systemic exposure is very low, supporting its classification as acting predominantly within the colon rather than systemically.drugbank+1
Because absorption is poor and metabolism occurs mainly via colonic bacteria, lactitol has negligible direct systemic pharmacodynamic activity and limited potential for classic systemic drug–drug interactions.drugs.ncats+2
Renal elimination of unchanged lactitol is minimal; thus, routine dose adjustment in mild to moderate renal impairment is usually not required, although general caution is advisable in severe renal or hepatic disease.drugs+1
Adverse effects, contraindications and toxicity
Common adverse effects reflect its gastrointestinal mode of action and include abdominal pain, bloating, flatulence and diarrhoea, which can lead to dehydration and electrolyte disturbances at higher doses or in sensitive patients.clevelandclinic+4
Hypersensitivity reactions (skin rash, pruritus, urticaria or angio‑oedema) are uncommon but clinically important, and any signs of allergy warrant discontinuation and medical assessment.medpedia.framar+2
Lactitol is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction, inflammatory bowel disease affecting the colon, and acute surgical abdomen (for example ileus), as well as in individuals with galactosaemia according to some product information.mims+3
From a toxicological perspective, serious systemic toxicity is rare; overdose presents primarily with severe diarrhoea, abdominal cramps and risk of water–electrolyte imbalance and dehydration, managed supportively with dose reduction or discontinuation and rehydration.pubmed.ncbi.nlm.nih+3
Use in pregnancy and lactation
Human pregnancy data for lactitol are limited, and manufacturers often refrain from assigning a specific risk category, recommending individual risk–benefit assessment before use.drugs+2
Experience with related osmotic laxatives such as lactulose suggests that minimal systemic absorption and local colonic action are compatible with use during pregnancy at recommended doses, with no signal for teratogenicity; extrapolation to lactitol supports a low expected fetal risk when clinically needed.nhs+2
Specific data on excretion of lactitol into breast milk and its effects on breastfed infants or milk production are lacking, and some sources advise weighing the importance of treatment to the mother against the unknown risks for the nursing infant.drugs+1
However, osmotic laxatives in general (for example lactulose, glycerol, macrogol) are considered suitable options for managing constipation in breastfeeding women, given their low passage into milk and essentially local gastrointestinal action, and lactitol is pharmacologically analogous.thewomens+3
Given the minimal systemic absorption of lactitol and its sugar alcohol nature, significant exposure via breast milk is unlikely, and adverse effects in the infant would theoretically be limited to potential mild gastrointestinal symptoms; nonetheless, prudence dictates use of the lowest effective dose and clinical monitoring of the breastfed child.breastfeedingnetwork+3
In lactating women, osmotic laxatives are generally preferred over stimulant laxatives, especially for longer‑term management of constipation, so lactitol can be considered an option where available, after consultation with a healthcare professional experienced in breastfeeding pharmacotherapy.thewomens+2
Practical lactation‑toxicology considerations
For short‑term treatment of constipation in breastfeeding mothers, lactitol’s local colonic mechanism and minimal systemic bioavailability support a low expected risk for the breastfed infant, particularly compared with systemically absorbed agents.accessdata.fda+3
Choice of laxative during lactation should also consider maternal comorbidities (for example diabetes, hepatic disease), concurrent medications and the wider evidence base; where extensive data exist for alternatives such as lactulose, those agents may remain first‑line, reserving lactitol for selected cases.nhs+3
When lactitol is used in a nursing woman, clinicians should monitor stool consistency, frequency and gastrointestinal tolerance in the mother, and remain alert to diarrhoea or irritability in the infant, adjusting the dose or switching therapy if concerns arise.clevelandclinic+3
Documenting the indication, dose, duration and observed effects in the breastfeeding dyad contributes to pharmacovigilance in this relatively under‑studied area and supports future refinement of lactation‑toxicity profiles for osmotic laxatives.cbg-meb+2



